Skip to main content
. 2022 Jan 6;12:784861. doi: 10.3389/fimmu.2021.784861

Figure 1.

Figure 1

Case summary. (A) Summary of disease course, treatment procedure, and key molecular findings. PR, partial response; CR, complete response; PD, progressive disease; mo, months. (B) H&E, HER2, and PD-L1 staining of the primary tumor and lung metastasis. Scale bars: 25 µm. H&E: hematoxylin and eosin. (C) Detailed molecular alterations of the primary tumor and lung metastasis. FC, fold change; MSS, microsatellite stable; TMB, tumor mutational burden.